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OBJECTIVE—To validate a case deﬁnition for diabetes in the pediatric age-group using ad-
ministrative health data.
RESEARCH DESIGN AND METHODS—Population-based administrative data from
Manitoba, Canada for the years 2004–2006 were anonymously linked to a clinical registry to
evaluatethevalidityofalgorithmsbasedonacombinationofhospitalclaim,outpatientphysician
visit, and drug use data over 1–3 years in youth 1–18 years of age. Agreement between data
sources, sensitivity, speciﬁcity, negative (NPV) and positive predictive value (PPV) were evalu-
ated for each algorithm. In addition, ascertainment rate of each data source, prevalence, and
differences between subtypes of diabetes were evaluated.
RESULTS—Agreementbetweendatasourceswasverygood.Thediabetesdeﬁnitionincluding
oneor more hospitalizationsor two or more outpatient claims over 2years providedasensitivity
of 94.2%, speciﬁcity of 99.9%, PPV of 81.6% and NPV of 99.9%. The addition of one or more
prescription claims to the same deﬁnition over 1 year provided similar results. Case ascertain-
ment rates of both sources were very good to excellent and the ascertainment-corrected preva-
lence for youth-onset diabetes for the year 2006 was 2.4 per 1,000. It was not possible to
distinguish between subtypes of diabetes within the administrative database; however, this lim-
itation could be overcome with an anonymous linkage to the clinical registry.
CONCLUSIONS—Administrative data are a valid source for the determination of pediatric
diabetes prevalence that can provide important information for health care planning and eval-
uation.
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D
iabetes prevalence continues to rise
in all age-groups, including chil-
drenandadolescents(1,2).Inorder
todescribetheburdenofdiseaseandeval-
uate strategies for disease prevention and
treatment, reliable population-based data
are required on an ongoing basis. Vital
statistics ﬁles, disease speciﬁc registries,
and surveys are all potentially useful and
adaptable to this purpose (2). Health ad-
ministrative data are an additional poten-
tial data source that is not as costly and
timeconsumingtoestablishandmaintain
and is thus more feasible to study (3).
Such data are also easily accessible on an
ongoingbasisandcan thusprovidecross-
sectional and longitudinal information.
A case deﬁnition using administrative
data has been validated for adult-onset
diabetes(.20yearsofage)andisusedby
Health Canada in the National Diabetes
Surveillance System (NDSS), which is a
network that gathers anonymous data
foraggregateanalysisfromprovincialsur-
veillance systems across Canada. The
NDSS diabetes case deﬁnition includes
one hospitalization or two outpatient vis-
its for diabetes over a 2-year period (4).
Because all data sources have poten-
tial limitations and the sensitivity and
speciﬁcity of administrative databases
have been reported to vary considerably
according to the disease studied (5), val-
idation of the data source for the given
disease and population of interest is es-
sential. Although a number of studies
have evaluated the prevalence of youth-
onset diabetes using administrative data
(6–10) only one has attempted to system-
atically validate a pediatric speciﬁc case
deﬁnition. Guttmann et al. (11) assessed
the sensitivity and speciﬁcity of a number
of deﬁnitions using hospital and outpa-
tient claims over 1 or 2 years in youth
aged ,19 years in the province of
Ontario, Canada. They found that the
NDSS deﬁnition had a sensitivity of
100% and a speciﬁcity of 94.2% in this
age-group. These results have not yet
been conﬁrmed with other datasets, nor
have the contribution of drug use data
and the determination of differences be-
tween type 1 and type 2 diabetes been as-
sessed in youth (11).
RESEARCH DESIGN AND
METHODS—Eighteen youth-onset
(age 1–18 years) diabetes case deﬁnition
algorithms were evaluated using combi-
nations of physician, hospital and drug
use data over 1, 2, and 3 years (Table 1).
Validation of these algorithms was per-
formed by comparing them to conﬁrmed
cases in a clinical registry. Case ascertain-
ment rates were also determined and dif-
ferences between type 1 and type 2
diabetes were evaluated. Finally, clinical
differences between identiﬁed cases (true
positives)andmissedcases(falsenegatives)
were evaluated.
Data sources
1) The Manitoba Health Services Insurance
Plan (MHSIP) contains registration ﬁles,
physician reimbursement claims, hospital
discharge abstracts, and records of pre-
scriptions dispensed. Canada has a single-
payer health system, and nonparticipation
is minimal because residents are not
charged health care premiums. These data
are stored for research purposes (University
of Manitoba Research Ethics Board and
Health Information Privacy Committee
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ORIGINAL ARTICLEapproval required) in de-identiﬁed form
in the Population Health Research Data
Repository (herein referred to as the Re-
pository) housed at the Manitoba Centre
for Health Policy in the University of
Manitoba’s Faculty of Medicine. Physician
reimbursement claims include Interna-
tional Classiﬁcation of Diseases, 9th Re-
vision, and Clinical Modiﬁcation (ICD-9
CM) diagnostic codes at the 3-digit code
level. Hospital records include ICD-9CM
codes at the decimal level up until 1 April
2004 and ICD-10 Canadian version (ICD-
10CA) codes thereafter. The ICD-9CM
code 250 (diabetes mellitus) and ICD-10-
CAcodesE10(insulin dependentdiabetes)
and E11 (noninsulin dependent diabetes)
were evaluated in this study.
Data on all prescriptions dispensed
by pharmacies are also available since
1995 in the pharmacy database, which
is a subset of the Drug Programs Infor-
mation Network (DPIN). The Anatomic
Therapeutic Chemical (ATC) code A10
(drugs for diabetes) was used.
2) The Manitoba Diabetes Education
Resource for Children and Adolescents
(DER-CA) Registry is located in the only
tertiary care pediatric referral center for
Manitobaandisknowntofollowover90%
of children in the province with type 1
diabetes (10). The DER-CA also follows a
large number of youth with type 2 di-
abetes. All youth followed in the DER-CA
since 1986 have been prospectively en-
tered into a clinical diabetes registry. The
registry contains personal health identiﬁ-
cation numbers (PHIN) and validated
diagnostic data that distinguish the sub-
typesofdiabetes.Thediagnosisofdiabetes
was made according to the criteria of
the Canadian Diabetes Association (12),
which are consistent with those of the
AmericanDiabetesAssociation(13).Using
de-identiﬁedPHINcodesandthroughthe
creation of a cross-walk ﬁle to the Re-
pository,youthcanbelinkedbetweendata
sources at the person level. All youth with
prevalent diabetes and valid Manitoba
PHIN codes between 1 and 18 years of
age from 1 January to 31 December 2006
were included in this study. Individuals
that did not have coverage data available
in the Repository for the full time period
evaluatedineachalgorithm(i.e.,1,2,or3
years) were excluded from that particular
analysis.
Validation methods and analysis
Thekstatistic(k)wasusedtomeasurethe
agreement between the two data sources
for the presence or absence of diabetes. A
kof0.80wasconsideredverygoodagree-
ment.Asensitivityandspeciﬁcityanalysis
of each proposed algorithm was con-
ducted, using the DER-CA database as
the “gold standard”. In addition, negative
predictive value (NPV) and positive pre-
dictive value (PPV) were determined. The
total midyear population of children 1–
18 years of age in Manitoba in 2006 was
268,120, which was considered the total
population at risk for diabetes. The two-
source capture, recapture method was
used to assess the ascertainment rate of
the Repository and DER-CA for youth-
onset diabetes in Manitoba as well as to
determine the ascertainment-corrected
prevalence of diabetes for 2006 (14).
Differences between type 1 and
type 2 diabetes
DuetothefactthattheICD9-CMcodesin
the administrative physician visit data do
not distinguish between the subtypes of
diabetes, it was not possible to identify de
novothesubtypesintheRepositoryusing
any of the proposed algorithms.
TheclinicalregistryfromtheDER-CA
contains validated diagnostic data which
distinguish the subtypes of diabetes. It
was used to determine the prevalence of
each subtype of diabetes in Manitoba
youth in 2006. Once individuals were
identiﬁedaseitherhaving type1ortype2
diabetes, they were anonymously linked
back to the Repository to determine what
percentage of each subtype of diabetes
was also present in the Repository data
using each of the 18 algorithms. In addi-
tion, drug use (i.e., ATC code A10 from
2004–2006) was examined to determine
if it would permit the differentiation of
subtypes of youth-onset diabetes within
the Repository.
Differences between identiﬁed cases
and false negative cases
In order to identify factors potentially re-
sponsibleforthecasesmissedbytheNDSS
deﬁnition (i.e., false negatives), difference
in age, sex, urban versus rural residence,
socioeconomic status and type of diabetes
(type2 vs.type1)were comparedbetween
the true positives and the false negatives
using t tests and x
2 tests as appropriate.
RESULTS
Validation of diabetes algorithms
Table 2 contains the validation results for
each youth-onset diabetes algorithm.
Overall, the agreement between the two
data sources was moderate to very good
with k values of 0.57–0.89. The sensitiv-
ity was high for all algorithms (88.9–
98.5%). Not surprisingly, the sensitivity
was higher if only one physician claim
was required rathert h a nt w oo rm o r e .
However, these algorithms had much
lower PPVs thanthose requiring twophy-
sician claims. The algorithm with the
highest PPV was #2, which included at
least one hospital claim or two physician
Table 1—Algorithms applied and validated to develop case deﬁnition for youth-onset
diabetes using Manitoba administrative data
Years of data
collection Algorithm #
Hospital
separation or
Physician
claims or
DPIN
records
1 (2006) 1 1 or more 1 or more —
2 1 or more 2 or more —
3 1 or more 1 or more 1 or more
4 1 or more 2 or more 1 or more
5 1 or more 1 or more 2 or more
6 1 or more 2 or more 2 or more
2( 2 0 0 5 –2006) 7 1 or more 1 or more —
8 1 or more 2 or more —
9 1 or more 1 or more 1 or more
10 1 or more 2 or more 1 or more
11 1 or more 1 or more 2 or more
12 1 or more 2 or more 2 or more
3( 2 0 0 4 –2006) 13 1 or more 1 or more —
14 1 or more 2 or more —
15 1 or more 1 or more 1 or more
16 1 or more 2 or more 1 or more
17 1 or more 1 or more 2 or more
18 1 or more 2 or more 2 or more
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Dart and Associatesclaims over a 1-year period. The addition
of DPIN data to the algorithm including
1 year of data (#4) improved the sensitiv-
ity from 88.9 to 94.2% as compared with
algorithm #2 while maintaining a rela-
tively good PPV of 82.4%. In contrast,
the addition of DPIN data to the algo-
rithms including 2 or 3 years of data did
not signiﬁcantly improve the sensitivity
and decreased the PPV slightly. This sug-
gests that if at least 2 years of data are in-
cluded, outpatient claim data provide an
adequate case ascertainment, not im-
proved by the addition of drug use data.
The speciﬁcity and NPV of all algorithms
were between 99.7 and 99.9%.
The ascertainment rate of the Repos-
itory for youth-onset diabetes for all di-
abetes algorithms ranged from 88.9 to
98.5%. The ascertainment rate for the
DER-CA had a wider range depending on
the algorithm evaluated (41.4–86.1%).
Prevalence of youth-onset diabetes
The ascertainment-corrected prevalence
of youth-onset diabetes in 2006 ranged
between2.30and4.84per1,000children
aged 1–1 8y e a r si nM a n i t o b a( T a b l e2 ) .
Differences between type 1 and
type 2 diabetes
There were a total of 531 prevalent youth
with diabetes (420 with type 1 and 111
with type 2 diabetes) identiﬁed from the
DER-CA registry that had full coverage
from 1 January to 31 December 2006 in
t h eR e p o s i t o r y .T h ep r e v a l e n c eo ft y p e1
diabetes was 1.57 per 1,000 and the
prevalence of youth-onset type 2 diabetes
was 0.41 per 1,000. These ﬁgures are
probably underestimates (i.e., minimum
prevalence rates).
T h em a j o r i t yo ft h ey o u t hw i t ht y p e1
diabetes were captured by all deﬁnitions
(91.9–99.3%); however, the percentage of
youth with type 2 diabetes captured was
more varied (77.5–95.5%). The algo-
rithms requiring two physician visits
rather than one decreased the likelihood
of a case being identiﬁed (77.5 vs. 92.8%
over 1 year and 88.3 vs. 93.7% over 2
years), indicating that many youth with
type 2 diabetes had only one billed physi-
cian encounter in that calendar year.
The drug data revealed that 96.8% of
youth with type 1 diabetes (n = 396) and
63.6% of youth with type 2 diabetes (n =
70) were dispensed a medication for di-
abetes. The youth with type 1 diabetes
were only dispensed insulin; however,
42.7% (n = 47) of the youth with type 2
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Validation of a pediatric diabetes case deﬁnitiondiabetes were dispensed only insulin,
13.6% were dispensed only an oral hypo-
glycemic agent (n = 15), and 7.3% (n =8 )
were dispensed both insulin and an oral
hypoglycemic agent. The oral agents
prescribed were metformin (60.0%),
glyburide (36.3%), and other (3.8%).
Differences between identiﬁed cases
(true positives) and false negatives
There was no difference between true
positive and false negative cases with
respect to age at diagnosis, sex, urban
versus rural residence, or socioeconomic
status (data not shown). There was,
however, a statistically signiﬁcant differ-
ence in the proportion of youth-onset type
2 diabetes (as a percentage of all diabetes)
i nt h et r u ep o s i t i v eg r o u p( 9 8 / 5 0 0=
19.6%) vs. the false negative group (13/
31 = 41.9%); P = 0.003.
CONCLUSIONS—This study sup-
ports the use of population-based ad-
ministrative data to evaluate diabetes
prevalence in youth 1–18 years of age in
single-payer health systems, such as the
one that exists in Canada. Deﬁnitions
that included 3 years of data were the
most sensitive (97.9–98.5%), but had
the worst PPV (40.0–77.4%), as more
false positives were identiﬁed with the
longer time period. The examination of
2 years of data rather than 1 year in-
creased the sensitivity of the deﬁnition
(94.2 vs. 88.9%), while sacriﬁcing only
slightly the PPV (81.6 vs. 86.1%). Algo-
rithms that required at least two outpa-
tient physician visits increased the PPV
markedly over those that only required
one, as more “true” cases were being de-
tected with the more restrictive deﬁni-
tions. The addition of one or two
prescription claims for a diabetes drug
improved the sensitivity slightly (94.2
and 96.8 vs. 88.9%) for 1 year of data.
Speciﬁcity and NPV were excellent
(99.7–99.9%) for all deﬁnitions.
On balance, the overall best deﬁni-
tions for youth-onset diabetes were as
follows:
1. One year of data (#4): Any one of: one
or more hospitalizations or two or
more physician claims or one or more
prescriptionclaims(sensitivity 94.2%,
speciﬁcity 99.9%, PPV 82.4%, and
NPV 99.9%).
2. Two years of data (#8): Any one of:
one or more hospitalizations or two
or more physician claims (sensitivity
94.2%, speciﬁcity 99.9%, PPV 81.6%,
and NPV 99.9%).
The second deﬁnition is identical to
the one used by the NDSS (4) and thus
supports its use in children. Guttmann
et al. (11) also recently evaluated the val-
idity of different algorithms for pediat-
ric diabetes using hospital chart audits
in Ontario as the second data source.
The NDSS deﬁnition in their study was
found to have a sensitivity of 100%
and a PPV of 97.6%; however, the speci-
ﬁcity was only 94.2%. They also com-
pared physician claim–based algorithms
with and without hospital claims data
and found that the addition of hospital
data increased the number of false posi-
tives identiﬁed, and thus decreased the
speciﬁcity of the diabetes deﬁnition. The
authors hypothesized that this inaccuracy
was caused by secondary causes of diabe-
tes being coded as diabetes in the inpa-
tient setting. This ﬁnding is difﬁcult to
interpret in the context of hospital chart
review as the validation source. The most
speciﬁcd e ﬁnition in their study was four
outpatient visits over a 2-year period.
However, two claims in a 2-year period
had a higher sensitivity with only a mar-
ginal difference in speciﬁcity (98.6 vs.
98.9%).
A summary of the pediatric diabetes
literature that has used administrative
data to evaluate diabetes prevalence is
provided in Table 3. Blanchard et al. (10)
used Manitoba administrative data be-
tween1985and1993toevaluate0-to14-
year-oldsspeciﬁcallywithtype1diabetes.
The case deﬁnition used was ﬁve or more
physician claims or a minimum of three
physician claims if registered with
Manitoba Health for less than 2 years
(10). Individuals with treaty status were
excluded from that analysis as a proxy in
order to evaluate only children with type
1 diabetes (10). Treaty status refers to in-
dividuals of Aboriginal descent included
in the Indian Registry, established by the
Indian Act in 1876 (15). As the majority
of youth with type 2 diabetes in Manitoba
are Aboriginal, the availability of this in-
formation could allow the differentiation
between youth with type 1 and type 2 di-
abetes in future studies. The ethnicity of
youth with type 2 diabetes varies from
population to population, and therefore
this approach would not necessarily be
generalizable.
Rhodes et al. (16) used a Boston
Massachusetts database to evaluate inpa-
tient or outpatient ﬁve-digit ICD-9CM
codes in youth and young adults with di-
abetes. The PPV was 97% for type 1 di-
abetes but only 16% for type 2 diabetes,
likely due to the fact that unspeciﬁed
diabetes has the same ﬁve digit code.
Kemper et al. (17) evaluated encounter
and pharmacy claims in privately insured
children in the U.S. over 1 year. They
found that 10% of children with type 1
diabetes identiﬁed with claims data alone
were not on insulin, suggesting that
claims data alone may have a poor PPV.
Theseresultsareinkeepingwithourﬁnd-
ing that drug use data improved the PPV
when using only 1 year of data.
Two studies used the Indian Health
Service Facility Database in the U.S.
(9,18). The study by Dabelea et al. (18)
used a deﬁnition of one or more inpatient
oroutpatientrecordsover3yearstoiden-
tify cases of diabetes, but reported that
only 50%ofcasesidentiﬁedbytheIndian
Health Service were conﬁrmed by chart
audit, suggesting that the PPV of the def-
inition was very low. These results are
supported by this study, which showed
that algorithms with two or more outpa-
tient records, and using only 1 or 2 years
of data are more valid than those includ-
ing only one outpatient record and/or 3
yearsofdata.Thestudy byActonetal.(9)
used only one outpatient code to identify
cases with diabetes. The higher diabetes
prevalence they identiﬁed therefore likely
is also an overestimate (9). Two studies
have evaluated prescription claim data
aloneintheU.K.(6).andU.S.(7).toeval-
uate the prevalence of diabetes. Neither
study evaluated their methodology com-
p a r e dw i t ho t h e ra d m i n i s t r a t i v ea l g o -
rithms. Further study is required to
assess the validity of drug claim data
alone.
Administrative databases have been
criticized for being incomplete or inaccu-
rate (19). There has been concern that
health care encounters may not be billed
for, and thus do not appear in the data.
Alternatively, even though care may be
billed for, the correct diagnosis may not
be recorded (5). In addition, diagnoses
listed may be a reﬂection of testing per-
formed rather than diagnosis made. De-
spite these concerns, databases are
extensively used in research. Database re-
search offers the possibility of feasibly fol-
lowing individuals with chronic diseases
such as diabetes cross-sectionally and
longitudinally at a much reduced cost
and improved feasibility as compared
with other means (20). These concerns,
however, highlight the importance of
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based algorithms by assessing their valid-
ity, such as has been done in this study.
Ascertainment and diabetes
prevalence
The ascertainment of the Repository for
the diagnosis of youth-onset diabetes was
very good for all evaluated algorithms
(88.9–98.5%). This suggests that few
cases are likely to be missed if this admin-
istrative database is used to evaluate
youth-onset diabetes prevalence.
The two most favorable algorithms
provided youth-onset diabetes preva-
lence estimates of 2.40 and 2.43 per
1,000 youth. This estimate is comparable
to the crude prevalence of 1.82 per 1,000
in the U.S. evaluated by a recent active
surveillance initiative (21) and the Cana-
dian prevalence of 3 per 1,000 youth 1–
19 years of age reported by the NDSS (4).
Differences between type 1 and
type 2 diabetes
The main limitation of administrative
data in the evaluation of diabetes is the
inability to identify the subtypes of di-
abetes with three-digit ICD-9CM codes.
Thisislessofanissueinadultpopulations
where type 2 diabetes accounts for the
vast majority of cases. In the past, type 1
diabetes could be assumed on the basis of
pediatric age; however, with the increasing
prevalence of type 2 diabetes in children,
this is no longer the case (22).
In addition, even if ﬁve-digit ICD-
9CM coding is available, the PPV for the
diagnosisoftype2diabetesmaybeas low
as 16% (16). The current study evaluated
drug use in both subtypes of diabetes as a
potential means to differentiate type 1
from type 2 diabetes. However, lifestyle
management is the mainstay of treatment
in type 2 diabetes and is not captured in
thedrugusedatabase.Inaddition,insulin
remains the only approved pharmaco-
logic agent for the treatment of diabetes
in children in Canada and is the predom-
inant form of recommended pharmaco-
l o g i ct h e r a p yf o rb o t ht y p e1a n dt y p e2
diabetes in youth (12,23). Despite these
recommendations, however, clinical
practice is quite variable. A recent na-
tional surveillance study in Canada re-
vealed that 33% of individuals with type
2 diabetes were treated with lifestyle
alone, 27% with lifestyle and insulin,
22% with lifestyle and an oral hypoglyce-
micagent,and16%weretreatedwithlife-
style, an oral hypoglycemic agent, and
insulin (24). Thus, pharmaceutical use
cannot be used as a reliable means to dis-
tinguish one subtype of diabetes from the
other. Possible mechanisms to overcome
this limitation include linkages to clinical
registriessuchastheDER-CA,whichcon-
tain diagnostic data differentiating the
subtypesof diabetes or medical record re-
views or audits.
Of particular concern in this study
is the ﬁnding that youth with type 2
diabetesareover-representedinthefalse
negative group. This may be explained
byencountersbeingcodedwithanalter-
nate diagnosis or missed as the result of
lack of billing in an alternatively funded
arrangement or a nurse-only visit in a
local health center, or it may suggest a
Table 3—Pediatric studies evaluating the prevalence of diabetes using administrative data
Author Country
Data
source/years Code(s) Age (years)
Algorithm
(years of data
evaluated)
Validation
source
Guttmann
2010 (11)
Canada
(Ontario)
Institute for Clinical
Evaluative Sciences
ICD-9CM: 250.X ,19 1+ hospital or 2+
outpatient visits (2 years) vs.
Hospital charts
1994–2005 ICD-10: 10–14 1–5 outpatient visits 6
hospital claim
(1 or 2 years)
Dabelea
2009 (18)
United States
(Navajo Youth)
Indian Health
Service Facilities
2001–2005
ICD-9CM
250.0–250.9
,20 1+ outpatient visit or
hospitalization
(3 years)
Medical records
Hsia 2009 (6) United
Kingdom
Prescription records
1998–2005
ATC code A10 0–18 1+ prescription claim “General practice
research
database”
Cox 2008 (7) United States
(Missouri)
Prescription claims:
Scripts Inc.
Antidiabetic
drug
5–19 1+ prescription claim None
2002–2005
Kemper
2006 (17)
United States MarketScan: commercial
claims and encounter
database (Inpatient,
outpatient + drug data)
T1DM:
250.X1/X3
#18 T1DM: 1+ inpatient
or outpatient
code 6 insulin
Drug claim
data
1998–2002 T2DM:
250.X0/X2
T2DM: 1+ inpatient or
outpatient code 6
no insulin
Acton 2002 (9) United States Indian Health
Service Facilities
ICD-9CM
250.0–250.9
,35 1+ outpatient code None
1990–1998
Blanchard
1997 (10)
Canada
(Manitoba)
Outpatient visits
1985–1993
ICD-9CM 250 0–14 5 outpatient visits
or 3–4i f,2y e a r s
coverage
Diabetes
Education
Registry
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
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Validation of a pediatric diabetes case deﬁnitionpossible service inequity that should be
addressed.
CONCLUSIONS—This study sup-
ports the use of administrative data in a
single-payer health care system to deter-
mine the overall prevalence of diabetes
in youth at a population level. This data
source can feasibly provide cross-sectional
andlongitudinaldatawhichareimportant
in planning for health care use as well as
evaluating disease prevention and treat-
ment strategies. In order to differentiate
type 1 from type 2 diabetes, clinical corre-
lation is required.
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